Would you consider HIPEC in a known BRCA+ IIIC ovarian cancer patient undergoing interval debulking surgery if the patient is known to desire PARPi maintenance following completion of chemotherapy?

Yes. There is currently no known stratification for BRCA patients undergoing HIPEC. OVHIPEC1 demonstrated an 11 mo. OS benefit in stage III patients undergoing interval CRS with HIPEC. In this study, patients did not undergo maintenance PARPi. BRCA patients have previously reported to have better ou...